Date: 2017-05-04
Type of information: Milestone
Compound: novel small molecule RORgamma modulators for the treatment of autoimmune diseases
Company: Karo Bio (Sweden) - Pfizer (USA - NY)
Therapeutic area: Autoimmune diseases
Type agreement: R&D
Action mechanism:
Disease: autoimmune diseases
Details: Karo Bio has entered into a research collaboration agreement with Pfizer to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.
Financial terms: Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive right to market any products that may be developed as a result of the collaboration. Karo Bio may receive up to $217 million (€166 million) in upfront and milestone payments in addition to potential royalty fees.
Latest news:
- • On May 4, 2017, Karo Pharma announced the the company has received a milestone for the RORgamma project amounting to $ 2 million. This is the second milestone-payment for RORgamma.
- • On September 5, 2013, Karo Bio has announced that the collaboration with Pfizer has successfully resulted in a significant achievement within the RORgamma project triggering the first milestone payment to Karo Bio.
- • On June 26, 2013, Karo Bio has announced the extension of its existing research collaboration with Pfizer on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.
- The collaboration that started in December 2011, aims to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. Pfizer is responsible for all research costs of the project.
- The nuclear hormone receptor RORgamma is a novel attractive target for the treatment of autoimmune diseases like rheumatoid arthritis, multiple sclerosis and psoriasis. RORgamma directly controls the production and secretion of the cytokine IL-17, a major contributor to inflammation. The receptor’s key role in driving disease pathology has been implicated in clinical trials using monoclonal antibodies that neutralize IL-17 activity. The agreement with Pfizer was entered into after Karo Bio discovered novel, potent, and specific RORgamma modulators.
Is general: Yes
